Stem Cell Therapy
Stem Cell Therapy for Age-Related Macular Degeneration
This trial is for adults 50+ who are losing their vision due to dry age-related macular degeneration. A new treatment, ASP7317, which is a specially created type of cell derived from human stem cells, will be injected into the macula of the eye in an effort to slow or reverse atrophy.
Stem Cell Therapy
Stem Cell Therapy for Retinal and Optic Nerve Disorders
This trial will use stem cells from patients' own bone marrow to treat severe vision loss caused by retinal or optic nerve damage. The stem cells will be injected into the eye to help repair the damaged tissues. SCOTS is the largest ophthalmology stem cell study registered at the National Institutes of Health, using autologous bone marrow-derived stem cells for retinal and optic nerve diseases.
Monoclonal Antibodies
SUSVIMO for Age-Related Macular Degeneration
This trial will assess the response to treatment with SUSVIMO given every 24 weeks in patients with nAMD who have been previously treated with anti-VEGF agents. A substudy will evaluate the impact of SUSVIMO on corneal endothelial cells.
Gene Therapy
RGX-314 Gene Therapy for Age-Related Macular Degeneration
This trial is evaluating a potential new treatment for a disease that causes vision loss. The current standard of care for this disease requires life-long, repeated injections to maintain efficacy, but this new treatment would only require a single injection.
Complement Inhibitor
Danicopan for Age-Related Macular Degeneration
This trial is testing a medication called danicopan to see if it can help people with a specific type of eye disease called Geographic Atrophy, which is related to Age-related Macular Degeneration. The study will check how well the medication works, how safe it is, and how the body handles it.
Brain Stimulation
Active tDCS for Age-Related Macular Degeneration
This trial is testing whether a-tDCS, a kind of brain stimulation, can be combined with perceptual learning to improve the ability of people with age-related or juvenile macular degeneration to read words on a computer screen.
Popular Filters
Trials for Age-Related Macular Degeneration Patients
Behavioural Intervention
Scotoma Awareness Training for Low Vision
This trial tests a new training method for older adults with Macular Degeneration, a condition causing central vision loss. The training uses a simulated blind spot to help patients become aware of their vision loss and develop new ways to see better. By making patients aware of their blind spot, the training aims to improve their vision and daily functioning. Eccentric viewing training has been shown to improve near visual acuity, reading speed, and daily functioning in people with central vision loss.
Anti-VEGF Monoclonal Antibody
Zifibancimig for Age-Related Macular Degeneration
This trial is testing a new treatment called zifibancimig for people with a serious eye condition known as neovascular age-related macular degeneration (nAMD). The treatment is given either as an injection into the eye or through a small implant. It works by stopping harmful blood vessels from growing in the eye, which can help protect or improve vision.
Trials for AMD Patients
Behavioural Intervention
Scotoma Awareness Training for Low Vision
This trial tests a new training method for older adults with Macular Degeneration, a condition causing central vision loss. The training uses a simulated blind spot to help patients become aware of their vision loss and develop new ways to see better. By making patients aware of their blind spot, the training aims to improve their vision and daily functioning. Eccentric viewing training has been shown to improve near visual acuity, reading speed, and daily functioning in people with central vision loss.
Anti-VEGF Monoclonal Antibody
Zifibancimig for Age-Related Macular Degeneration
This trial is testing a new treatment called zifibancimig for people with a serious eye condition known as neovascular age-related macular degeneration (nAMD). The treatment is given either as an injection into the eye or through a small implant. It works by stopping harmful blood vessels from growing in the eye, which can help protect or improve vision.
Trials for ABCA4 Positive Patients
Vitamin A Derivative
ALK-001 for Stargardt Disease
This trial tests a special type of vitamin A called ALK-001 to see if it can safely slow down vision loss in people with Stargardt disease by reducing harmful substances in the eye. ALK-001 is designed to reduce the accumulation of toxic substances in the retina, which are associated with vision loss in Stargardt disease.
Complement Factor C5 Inhibitor
Zimura for Stargardt Disease
This trial is testing an eye injection medication to help people with Stargardt disease, a genetic condition that leads to vision loss. The medication aims to block harmful processes in the eye to prevent further vision loss.
Tinlarebant for Stargardt Disease
This trial is testing a medication called tinlarebant to see if it can slow down eye damage in teenagers with a condition called STGD1. About 90 participants will take tinlarebant for an extended period. The goal is to see if tinlarebant can help prevent their vision from getting worse.
Phase 3 Trials
Complement Inhibitor
Pegcetacoplan for Age-Related Macular Degeneration
This trial is testing a medication called pegcetacoplan to see if it is safe and effective for people with a severe eye condition called geographic atrophy, which is related to age-related macular degeneration. The medication aims to protect the eye by blocking harmful immune responses. Pegcetacoplan has shown an acceptable safety profile in previous studies for geographic atrophy.
Vascular Endothelial Growth Factor (VEGF) Inhibitor
OPT-302 + Aflibercept for Age-Related Macular Degeneration
This trial will compare a new treatment to a sham (fake) treatment in order to see if the new treatment is effective. The primary efficacy will be determined at Week 52, meaning that's how long the trial will last.
Gene Therapy
RGX-314 Gene Therapy for Wet Age-Related Macular Degeneration
This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. It aims to help the eye make its own medicine to stop harmful blood vessels from causing vision loss. This could reduce the need for regular injections. RGX-314 modifies the retina's cells to create a treatment that may only be needed once.
Trials With No Placebo
Behavioural Intervention
Scotoma Awareness Training for Low Vision
This trial tests a new training method for older adults with Macular Degeneration, a condition causing central vision loss. The training uses a simulated blind spot to help patients become aware of their vision loss and develop new ways to see better. By making patients aware of their blind spot, the training aims to improve their vision and daily functioning. Eccentric viewing training has been shown to improve near visual acuity, reading speed, and daily functioning in people with central vision loss.
Anti-VEGF Monoclonal Antibody
Zifibancimig for Age-Related Macular Degeneration
This trial is testing a new treatment called zifibancimig for people with a serious eye condition known as neovascular age-related macular degeneration (nAMD). The treatment is given either as an injection into the eye or through a small implant. It works by stopping harmful blood vessels from growing in the eye, which can help protect or improve vision.
View More Related Trials
Frequently Asked Questions
Introduction to macular degeneration
What are the top hospitals conducting macular degeneration research?
Macular degeneration, a leading cause of vision loss, is being tackled head-on by several top hospitals in different locations. In Reno, Sierra Eye Associates is making significant strides with 10 active macular degeneration trials and an impressive 48 completed trials to date. Since their first recorded trial in 2013, they have been dedicated to finding innovative solutions for this condition. Meanwhile, Cumberland Valley Retina Consultants in Hagerstown has been actively involved as well, with nine ongoing trials and a history of 16 previous studies since initiating their first macular degeneration trial in 2012.
Retina Consultants of Texas has also emerged as a key player on the medical landscape when it comes to fighting macular degeneration. Located both in Bellaire and The Woodlands, these institutions collectively conduct seventeen active clinical trials that aim to combat this sight-threatening disease. Their contributions span numerous years of research efforts since their initial ventures into macular degeneration trials: Bellaire began theirs in earnest back in 2015 while The Woodlands joined the fight more recently but not less enthusiastically beginning from only three years ago.
In Boston's Ophthalmic Consultants of Boston,a renowned institution engaging seven currently open clinical tests focusing primarily on combating macular degradation; altogether they have conducted forty-three such investigations already representing them one suitable option worth considering if one seeks treatment for preventing further risks.Their contribution dates quite far back compared to others starting way earlier around1999.
These esteemed hospitals provide hope for those affected by macular degeneration by fostering groundbreaking research and offering potential treatments that can improve patients' quality of life. Through tireless dedication and collaborative efforts across various locations nationwide these institutions strive towards better understanding this complex eye condition while actively developing strategies for its management ultimately aiming at restoring or preserving precious eyesight we all cherish
Which are the best cities for macular degeneration clinical trials?
When it comes to clinical trials for macular degeneration, several cities have emerged as leading hubs of research. Phoenix, Arizona, stands out with 32 active trials investigating treatments like RGX-314, IONIS-FB-LRx, and ADVM-022. Close behind is Austin, Texas, with 29 ongoing studies focusing on IONIS-FB-LRx, RGX-314, and Faricimab. Boston and Philadelphia tie with 25 active trials each that explore various treatment options such as RGX-314 Dose 2 and PEGCETACOPLAN (APL-2). Lastly, Baltimore has made significant contributions to the field with its 24 active trials studying interventions including RGX-314 and JNJ-81201887 High dose. These cities offer individuals affected by macular degeneration access to cutting-edge clinical trials that hold promise for advancements in care.
Which are the top treatments for macular degeneration being explored in clinical trials?
Promising treatments for macular degeneration are currently being explored in clinical trials. One such treatment is ALK-001, which has two active trials and a total of two all-time macular degeneration trials since its listing in 2015. Another contender is RGX-314, with two ongoing trials and four previous macular degeneration studies. Finally, there is RGX-314 Dose 2, which joined the scene in 2020 and already has two active trials alongside its two all-time macular degeneration trials. These innovative therapies offer hope for patients battling this debilitating eye condition.
What are the most recent clinical trials for macular degeneration?
Exciting progress is being made in the field of macular degeneration, with recent clinical trials offering promise for improved treatment options. One noteworthy trial involves NG101 gene therapy, which has progressed to Phase 2 after showing positive outcomes in Phase 1. Additionally, an experimental low-dose treatment has shown potential in early phases of development. Another study evaluated the efficacy of KH631 at its initial dose stage, while CT1812 at a dosage of 200 mg underwent Phase 2 testing. These trials mark significant advancements towards finding effective interventions for individuals suffering from macular degeneration.
What macular degeneration clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of macular degeneration, offering hope for improved treatments. Sandoz's trial on SOK583A1 was completed in May 2022, while Kodiak Sciences Inc concluded their study on KSI-301 in June 2021. In that same month, Maturi, Raj K., M.D., P.C.'s investigation into RBM-007 Injectable Solution also reached completion. These breakthroughs join a host of other notable trials like AsclepiX Therapeutics' AXT107 and EyePoint Pharmaceuticals' EYP-1901, both completed in early 2021. The collective efforts of researchers sponsored by various organizations such as Novartis Pharmaceuticals and Hoffmann-La Roche have paved the way for potential advancements against macular degeneration.